How Gilead Intends To Deliver On Promise Of Remdesivir For COVID-19

When the coronavirus hit China, Gilead only had enough remdesivir for 5,000 patients. Here’s how it went about expanding production.

conveyer

Gilead Sciences Inc.has begun sharing glimpses of the massive scaleup underway in the manufacture of its remdesivir, authorized in the US for emergency use and approved in Japan for treatment of the SARS-CoV-2 injection that causes COVID-19.

There are a growing number of clinical trials to supply as well as expanded access, compassionate use and emergency authorization...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance